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Hematopoietic stem cells derived from human em-
bryonic stem cells (hESCs) could provide a therapeu-
tic alternative to bone marrow transplants, but the
efficiency of currently available derivation protocols
is low. In this study, we investigated whether cocul-
ture with monolayers of cells derived from mouse
AGM and fetal liver, or with stromal cell lines derived
from these tissues, can enhance hESC hematopoi-
etic differentiation. We found that under such condi-
tions hESC-derived differentiating cells formed early
hematopoietic progenitors, with a peak at day 18–21
of differentiation that corresponded to the highest
CD34 expression. These hESC-derived hematopoi-
etic cells were capable of primary and secondary he-
matopoietic engraftment into immunocompromised
mice at substantially higher levels than described
previously. Transcriptional and functional analysis
identified TGF-b1 and TGF-b3 as positive enhancers
of hESC hematopoietic differentiation that can
further stimulate this process when added to the
culture. Overall, our findings represent significant
progress toward the goal of deriving functional
hematopoietic stem cells from hESCs.
INTRODUCTION
Transplantation of hematopoietic stem cells (HSCs) in leukemia
treatment requires high-quality sources of tissue-matched
bone marrow, mobilized peripheral blood, or umbilical cord
blood. Suitable bone marrow is often in short supply, and cord
blood, although bankable, contains much lower numbers of
HSCs, which makes it less suitable for adult transplantation.Directed differentiation of human embryonic stem cells (hESCs)
toward HSCs offers a potentially attractive alternative to these
conventional sources. The recent reports of somatic cell reprog-
ramming by means of induced pluripotency makes this ap-
proach an even more exciting prospect for future cell-based
therapies (Takahashi et al., 2007; Yu et al., 2007).
Embryoid body (EB)-induced differentiation of hESCs can re-
sult in hematopoietic colony-forming cells (CFCs), and this can
be further enhanced by BMP4 and a cocktail of cytokines, which
is used for the expansion of bone marrow progenitor cells (Ken-
nedy et al., 2007; Chadwick et al., 2003). Furthermore, it has
been shown that hematopoiesis from hESC may arise from
primitive endothelial-like cells that express PECAM-1, FLK-1
(KDR), and VE-Cadherin, suggesting the existence of an embry-
onic endothelium that possess hemagioblastic characteristics
(Wang et al., 2004). Coculture of hESC with stromal cell lines
such as S17 (Kaufman et al., 2001), OP9 (Vodyanik et al.,
2005), and fetal liver-derived stromal cells (Qiu et al., 2005) can
also result in spontaneous generation of hematopoietic cells;
however, the overall extent of hematopoietic development is
low (0.1%–2% of CD45+ during 8–20 days of differentiation).
This is also reflected in vivo, where hESC-derived progenitors
from coculture with S17 stromal cells engraft primary and sec-
ondary fetal sheep recipients with very low levels of chimerism
(0.001%–0.05% of the bone marrow; Narayan et al. [2006]).
The importance of embryonically derived HSCs has been
thoroughly investigated in the murine embryo, showing that the
first cells with long-term multilineage repopulation capacity that
colonize the fetal liver and the bone marrow from day 10 of ges-
tation arise in the aorta-gonad-mesonephros (AGM) region,
which comprises the splachnopleural mesoderm from the lower
trunk and caudal region of the embryo (Medvinsky and Dzierzak,
1996; Cumano et al., 2001). Culturing of the whole AGM region at
an air/liquid interface results in a 15-fold increase in the number
of HSCs, consistent with the hypothesis that this region pro-
duces factor(s) involved in the genesis, maintenance, and/or
amplification of these cells (Medvinsky and Dzierzak, 1996).Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc. 85
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Hematopoietic Differentiation of hESC on Stromal CellsThe work conducted in one of our groups indicates that coculture
of murine ESC with primary AGM tissue in whole-organ culture
and with a stromal cell line derived from that tissue results in en-
hanced hematopoietic differentiation (Krassowska et al., 2006).
We show in this study that primary stromal cells derived from
the AGM and fetal liver significantly enhance spontaneous he-
matopoietic differentiation in high-density hESC monolayer cell
cultures. The hESC-derived hematopoietic cells were capable
of primary and secondary hematopoietic engraftment into immu-
nocompromised NOD/LtSz-Scid IL2Rgnull recipients with up to
16% engraftment, which is significantly higher than described
previously. Large-scale transcriptional analysis combined with
signal blocking and overexpression experiments led to identifi-
cation of TGF-b1 and TGF-b3 as positive regulators of hESC
differentiation in this system.
RESULTS
Powerful Enhancement of Hematopoietic
Differentiation of hESCs by Stromal Cells
Derived from Hematopoietic Niches
One stromal cell line generated from the aorta/mesenchyme
part of the AGM region of 10 dpc murine embryos (AM20.1B4),
one from the urogenital ridge of the AGM region (UG26.1B6),
and one from the fetal liver (EL08.1D2) of 11 dpc embryos were
used in this study (Oostendorp et al., 2002a, 2002b, 2005a).
We also investigated whether the primary stromal cells derived
from the AGM (10.5 dpc) and fetal liver (12.5 dpc) region can en-
hance the hematopoietic differentiation of hESCs over a 25 day
time period. For direct comparison, the experiments between
stromal cell lines and primary cells were carried out in parallel
and using the same early passage (35–50) hESCs.
The stromal cells were mitotically inactivated and used in co-
culture experiments with hESCs over a 25 day differentiation
time course monitored by flow cytometry and CFC assays. Pilot
experiments with GFP-labeled hESCs cocultured with mitotically
inactivated stromal cells and mitotically active stromal cells were
carried out beforehand. This revealed no significant differences
in the hematopoietic induction of hESC (data not shown); hence,
mitotically inactivated stromal cells were used throughout this
study. From day 12 to day 21, tight cobblestone patterns of cells
appeared,and from day 18 onward differentiated cell types orga-
nized in ‘‘endothelial vessel’’ structures emerged (see Figures
S1A and S1B, available online). Differentiation of hESC was con-
firmed by the downregulation of two pluripotency markers,
OCT4 and NANOG (Figure S1C).
CD34+ cells appeared at day 6 of culture and peaked on day
18 in all cases except when cocultured with the AM20.1B4 cell
line (Figure 1A). The peak of CD34 expression corresponded
to the maximum number of CFCs obtained (see below,
Figure 2A). CD45+ cells appeared in small percentages in early
stromal cell cocultures (from day 6, Figure 1B) and peaked by
day 25; this occurs slightly later than in the cocultures with the
primary stromal cell lines derived from the AGM region and fetal
liver (Figure 1B). A small number of CD45+ cells were also iden-
tified in the control experiments in which hESCs differentiated in
the absence of stromal feeder cells; however, this is most likely
due to formation of a small number of EB structures resulting
from the high culture density, especially at the later time points86 Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc.(our own observations). CD31+ cells first appeared on day 6
and peaked on day 12 in the stromal cell line cultures and on
day 18 in the primary stromal cell cocultures (Figure 1C); how-
ever, the vast majority of them were CD34+CD31+ at these
time points (Figures 1C and 1D). KDR/VEGFR2 shows a biphasic
expression pattern in the stromal cell line cultures (Figure 1E): an
early expression peak between days 6 and 12 associated with
CD34 expression and a later peak between days 18 and 21,
not associated with CD34 expression (Figure 1F). This pattern
is not observed in the primary stromal cell cocultures in which
the peak of KDR expression at day 18 seems to correspond
with that of CD34+KDR+ (Figures 1E and 1F).
Using four-color flow cytometry analysis, we showed that
33.7% and 50.5% of CD34+KDR+ cells obtained from coculture
of hESC with AGM or fetal liver primary cells, respectively
(Figure S1D) were also CD31+VE-Cadherin+ consistent with the
presence of hemangioblast-like cells suggested by Wang et al.
(2004). A smaller percentage of such cells were also found in
the cocultures with the stromal cell lines (Figure S1E).
Hematopoietic CFC activity peaked at day 18 in all cases ex-
cept coculture with the AM20.1B4 cell line concurrent with the
peak of most hematopoietic markers described above (Figures
2A and 1A). A relatively low CFC activity was noticeable in the
control group differentiated in the absence of any stromal cells
by the end of differentiation process (days 21–25, Figure 2A),
though this was significantly less than during coculture with the
stromal cell lines and might be explained by the formation of
EB-like structures with low hematopoietic activity within dense
cocultures. As observed with murine ESC differentiation
(Krassowska et al., 2006), coculture with stromal cells derived
from primary AGM and FL regions resulted in a significant in-
crease in hematopoietic activity when compared to a no-feeder
control group.
Representative colonies from the differentiation of hESCs
showed typical morphology of various CFC subtypes, including
macrophages, granulocytes, and erythrocytes as well as mixed
colonies comprising different types of these cells (Figure 2B).
Colony identity was confirmed by Wright-Giemsa staining of cy-
tospin preparations (Figure 2C). Analysis of CFCs from coculture
with the stromal cell lines indicated a gradual decline in BFU-E
and CFU-E from day 6 in all three coculture systems (hESC-
AM20.1B4, hESC-EL08.1D2, and hESC-UG26.1B6, Figure 2D).
Cells within the CFU-G, CFU-M, and CFU-GM colonies were an-
alyzed by flow cytometry and found to be CD45+ and coexpress-
ing at least one of the following markers (CD64, CD33, and
CD14), indicating early myeloid or granulocytic lineage commit-
ment (Figures S2A–S2C). Erythroid cells were detected in mixed
colonies by their hemoglobinization, glycophorin A expression,
and the absence of CD45 expression (Figure S2D).
To prove these colonies were of human origin, DNA finger-
printing analysis was carried out on the hESCs and colonies
recovered from methylcellulose assays (Figure S2E). This analy-
sis, in addition to the complete absence of colonies arising from
mitotically inactivated primary cells derived from the AGM re-
gion, fetal liver, or stromal cell lines, confirmed the human origin
of hematopoietic colonies. Another observation was the pres-
ence of cells that lacked CD34 and CD45 expression but showed
expression of some typical MSC markers during coculture with
each of the three stromal cell lines as shown in Figure S3.
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Hematopoietic Differentiation of hESC on Stromal CellsFigure 1. Kinetics of Hematopoietic Differentiation of hESCs Cocultured with Stromal Cells
(A–F) Kinetics of CD34+ (A), CD45+ (B), CD31+ (C), CD34+CD31+ (D), KDR+ (E), and CD34+KDR+ (F) during hESC differentiation, n = 3–6; error bars represent SD
p values (for days on which peak expression was observed) for graphs shown in (A)–(F) and were calculated using arcsine transformation. All the antibodies used
were tested to ensure specificity for the human antigens only.Activation of Hematopoietic Gene Expression during
hESC Coculture with AGM and Fetal Liver-Derived
Stromal Cell Lines
To investigate in detail the hematopoietic differentiation of
hESC on immortalized stromal cells, we carried out quantitative
RT-PCR analysis for various genes that mark the development of
mesoderm, and differentiation into hematopoietic precursors or
more committed definitive hematopoietic cells. DNA sequencesof oligonucleotides used in all PCR reactions were designed to
amplify only the human ortholog. We found that expression of
two mesodermal markers, BRACHYURY and MIXL1, was
activated in the first 6 days of coculture, indicating formation
of mesodermal cells preceding the emergence of early
CD34+CD31+KDR+CD45 precursors on day 12 (Figure 3A).
Interestingly, the strongest activation of both genes occurred
during coculture of hESC with the AM20.1B4 cell line, which alsoCell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc. 87
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Hematopoietic Differentiation of hESC on Stromal CellsFigure 2. Hematopoietic Progenitor Capacity of hESCs Differentiating on Stromal Cells
(A) CFC activity of hESC differentiating on stromal cells as compared to no-feeder control (n = 4–8), error bars represent SD. Significance between each coculture
and no-feeder control was calculated using Student’s t test.
(B) Distribution of hematopoietic colony subtypes obtained under differentiation of hESC on primary stromal cells derived from the AGM region and the fetal liver
(n = 4–8).
(C) Wright-Giemsa stains of cytospin preparations of erythroid colonies (CFU-E and BFU-E), granulocytic (CFU-G), macrophage (CFU-M), and mixed colonies
(CFU-GM and CFU-GEMM).
(D) Distribution of hematopoietic colony subtypes obtained under differentiation of hESC on stromal cell lines.shows a later peak in CD34+ expression and CFC formation (Fig-
ures 2C and 3A). This suggests that AM20.1B4 is slightly more
efficient in encouraging hESCs to form mesoderm and perhaps
less-differentiated hematopoietic progenitor cells. This hypothe-
sis is further supported by the observation that three important
genes involved in early hematopoiesis in mice, SCL (Figure 3B)
GATA2, and LMO2 (data not shown), show the strongest upre-
gulation during coculture with the AM20.1B4 cell line.
Quantitative RT-PCR analysis for hemangioblast-related
markers KDR and CD31 (PECAM1) showed the strongest upre-
gulation during coculture with the UG26.1B6 and EL08.1D2 cell
lines at the early time points comprising days 6–18 (Figure 3B),
which also correlates with the maximal CFC activity observed
with these stromal cell lines (Figure 2A). Interestingly,88 Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc.CDX4 activation was obvious on day 6 in the EL08.1D2 and
UG26.1B6 cocultures followed by strong upregulation of
HOXB4 from day 12 onward (Figure 3B), suggesting the onset
of definitive hematopoiesis in these two cocultures. Additionally,
the expression of RUNX1/AML and PU.1 that is important for
definitive hematopoietic cell differentiation was best upregu-
lated in the UG26.1B6 coculture on day 18, which correlates
with peak CFC activity and CD34 expression in these cocultures
(Figure 3B).
Erythroid-like cells derived from hESCs coexpress high levels
of embryonic and fetal globins but little or no adult globins
(Chang et al., 2006). This necessitates the investigation of differ-
ent globin expression in erythroid cells obtained after CFC
assays. The specificity of each primer pair was investigated by
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bryo as positive controls; therefore, the lack of any PCR product
in the cells obtained from CFU-E/BFU-E would indicate lack in
expression rather than failure in the PCR procedure. It is well
known that coordinated switching of the a-like and b-like genes
results in the expression of embryonic Hb Gower-1(z232), fetal
Hb-F (a2g2), and adult Hb-A (a2b2). Additionally, there are other
structurally defined hemoglobins such as Gower-2 (a232), Port-
land-1 (z2g2), and Portland-2 (z2b2), which are expressed at low
levels in primitive and definitive erythroid cells primarily during fe-
tal and embryonic development. Expression analysis of these
possible globin combinations in CFU-E colonies indicated that
erythroid progenitors generated in the first 12 days of differenti-
ation are likely to express Gower-1, fetal Hb-F, and Portland-1
(Figure 3C); however, from day 12 onward, only the Gower-2
form can be produced. The same analysis on CFU-Es taken
from different days of differentiation showed a reduction in the
expression of z2 and g2 chains and therefore little expression
of the embryonic Gower-1, Portland-1, and Hb-F, which sug-
gests that Gower-2 was the predominant combination in the first
18 days, while fetal Hb-F and Gower-2 were coexpressed from
day 18 onward (Figure 3C).
The Hematopoietic Induction Effect Is Not Entirely
Retained in the Conditioned Media
To understand the nature of the induction events, we separated
the two cell types using transwell inserts. Flow cytometry analy-
sis showed large reductions in hematoendothelial cell surface
marker expression (data not shown). Interestingly, the total num-
ber of CFCs was significantly reduced when transwell inserts
were used in combination with UG26.1B6 and EL08.1D2 cell
lines (Figure 4A), due to the complete absence of CFU-E and
BFU-E and significant reduction in other CFC types in both cell
lines. In contrast, the conditioned medium from the AM20.1B4
cell line resulted in the maintenance of CFC activity with the
majority of colonies being of the CFU-M type (Figure 4A). A
significant reduction in hematopoietic cell surface marker
expression and lack of CFC activity was also noted when trans-
well inserts were used during the coculture of hESC with primary
stromal cells derived from 10.5 dpc AGM and 12.5 dpc fetal liver
region, with CFCs from these experiments giving rise only to very
few CFU-M on day 12, resulting in 98% loss of hematopoietic
CFC activity (data not shown).
The Hematopoietic Induction Effect Is Not Entirely
Retained in the Extracellular Matrix of the Stromal
Cell Lines
To investigate whether the extracellular matrix (ECM) extracted
from the stromal cell lines retains their hematopoietic inducing
activities, we isolated the pericellular matrix from the cells using
deoxycholate and cultured hESC on this matrix for 18 days in
the presence of FCS-containing media (ECM+FCS medium,
Figures 4B–4D). In all three cases, CFC capability declined; how-
ever, there were large variances between the cell lines with
AM20.1B4 retaining 30% of the CFC activity, while EL08.1D2
and UG26.1B6 retained only 2% and 7%, respectively (Figures
4B–4D). When the FCS-containing medium was conditioned by
the cells and combined with ECM, hematopoietic activity was
lost for UG26.1B6 and EL08.1D2 (Figures 4C and 4D). In thecase of AM20.1B4, we noticed more terminal differentiation
(only CFU-M was observed instead of CFU-G, M, and CFU-
GM) for FCS-conditioned medium combined with the ECM of
this cell line, which again correlates with the transwell data show-
ing that CFU-M was the predominant colony type formed
(Figure 4B). To better define the culture conditions for hemato-
poietic differentiation of hESCs, we cultured these cells on
ECM derived from each of the cell lines in serum-free medium
(stem line, Sigma) supplemented with three human cytokines
(SCF, TPO, FLT-3L) or five human cytokines (BMP4, SCF, FLT-
3L, TPO, and VEGF-A165) as described by Tian et al. (2004).
Addition of the three cytokines to the serum-free medium in com-
bination with the ECM derived from the stromal cell lines resulted
in complete abrogation of the hematopoietic activity in the
AM20.1B4 cell line and retention of only 36% and 6.4% of this
activity in the EL08.1D2 and UG26.1B6 cell lines, respectively
(Figures 4C and 4D). Supplementation of the serum-free media
with five cytokines and combination with ECM abolished hema-
topoietic CFC activity of all three stromal cell lines (Figures 4B–
4D), corroborating previous data by Tian et al. (2004). Similar
experiments carried out with ECM extracted from primary
AGM or FL stromal cells showed a total loss of hematopoietic
CFC activity, indicating that direct cell-to-cell contact was cru-
cial for ESC differentiation on primary stromal cells.
Investigation of Molecular Pathways Involved
in the Hematopoietic Inductive Effect
To better define the molecular mechanisms modulating the
hematopoietic differentiation of hESC cocultured with stromal
cells, potential hematopoietic signaling pathways were modu-
lated. Gene expression analyses from macroarray (Oostendorp
et al., 2005b) and microarray data (Figure S4) of the three murine
stromal cell lines used in this study as well as a number of docu-
mented hematopoietic regulators (VEGFR2, SDF1, IL6, M-CSF,
TPO, and GM-CSF) were taken together to produce a list of can-
didates, which might mediate hematopoietic induction. Cocul-
tures with UG26.1B6 were used for these experiments, since
these produced the highest number of CD45+ cells when com-
pared to the other two stromal cell lines (Figure 1B). Chemical
or antibody inhibitors for these factors were added to the differ-
entiation media for 18 days at optimal inhibitory concentrations
(Table S1). Since the expression of CD45 closely correlated to
the CFC activity, flow cytometry analysis for this marker was
used to identify possible effects on the hematopoietic differenti-
ation of hESCs.
Several of the identified candidates including members of the
FGF family (FGF 7 and 9), members of the IGF family (IGF2), and
IGF binding proteins (IGFBP3 and 4), cytokines (IL6, IL3, IL1, M-
CSF, GM-CSF, TNFa), chemokines (CCL2, CCL5, SDF1), and in
particular candidates linked to the TGF-b superfamily of signal-
ing factors (TGF-b1–3, Activin, BMP4, and BMP2) modulate
the induction of CD45+ cells from hESC. Both stimulating and
inhibitory activities were found with the TGF-b family members.
Inhibition of the Activin receptor 1b (ALK4), TGF-b receptor 1
(ALK5), and Nodal receptor 1 (ALK7) by ALK 4-5-7 resulted in
the most significant changes in cell morphology (data not shown)
and decrease of hematopoietic marker expression during dif-
ferentiation, whereas inhibition of BMP4 alone, BMP4 and
BMP2 together (via Gremlin), Activin receptor type 1b (ALK4),Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc. 89
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Hematopoietic Differentiation of hESC on Stromal CellsFigure 4. Hematopoietic Activity Is Not Entirely Retained in the Conditioned Media or the ECM of the Stromal Cell Lines
(A) Hematopoietic CFC activity in the presence and absence of transwell insets at day 18 of hESC differentiation on stromal cell lines. Significance between
normal coculture and transwell inset culture was assessed by Student’s t test, p < 0.05.
(B–D) Hematopoietic CFC activity of hESC after 18 days of differentiation on ECM isolated from the AM20.1B4 stromal cell line (B), UG26.1B6 (C), and EL08.1D2
(D) and in the presence of serum-free medium and cocktails of three (SCF, TPO, and FLT-3L) or five (BMP4, SCF, VEGF-A165, FLT-3L, and TPO) cytokines.
Significance between normal cocultures and new methods used to induce hESC differentiation was calculated by using Student’s t test.and TGF-b2 via binding of TGF-b soluble receptor III (betaglycan)
resulted in a significant increase in CD45 expression (Table S1),
suggesting that these later factors were unlikely to account for
the significant decrease in hematopoietic commitment observed
upon application of ALK 4-5-7. Instead, inhibition of TGF-b1 and
TGF-b3 alone resulted in a significant decrease in CD45 expres-
sion (Table S1).
To investigate the role of some of the TGF-b family members in
more detail, we added to our coculture system human soluble
TGF-b1, -2, and -3, BMP4 (Figure 5A), and Activin A (data not
shown) in a dose-dependent manner. This showed that both
TGF-b1 and TGF-b3 enhance hematopoietic differentiation of
hESC cocultured with the UG26.1B6 cell line most effectively at
different concentrations (TGF-b1, 20 ng/ml; TGF-b3, 20–80 ng/ml;
Figure 5A). In contrast, TGF-b2 (20–100 ng/ml), BMP4 (20 ng/ml;
Figure 5A), and Activin A (1–30 ng/ml; data not shown) reduced
CD45 expression, pointing to a negative role for these factors in
hematopoietic commitment of hESCs in this coculture system
when added for the whole length of differentiation period(Figure 5A). Addition of soluble human TGF-b1 or TGF-b3 to dif-
ferentiating hESCs cocultured in the presence or absence of the
other stromal cell lines or primary cells indicated a significant in-
crease in hematopoietic commitment of hESCs (Figure 5B), sug-
gesting that addition of these two growth factors is beneficial to
their differentiation.
Expression analysis of a number of TGF and BMP family mem-
bers, receptors, and modulators (Figure S4) indicated that Tgfb1
is expressed at higher levels in the AM20.1B4 compared to
UG26.1B6 and EL08.1D2. Quantitative RT-PCR analysis con-
firmed that Tgfb1 was most highly expressed in AM20.1B4 com-
pared to the other stromal cell lines and primary cells derived
from the AGM and FL region (Figure 5C). In contrast, highest
Tgfb3 expression was seen in primary cells from the AGM region
and the UG26.1B6 cell line (Figure 5C). A similar analysis for hu-
man TGFb1 and TGFb3 expression indicated a gradual increase
in their expression during the differentiation time course (Figures
5C and 5D). Similar investigations carried out with hESCs cocul-
tured with primary stromal cells derived from the AGM and FLFigure 3. Expression of Mesodermal, Hematopoietic, Endothelial, and Homing Markers during hESC Differentiation
(A and B) Quantitative RT-PCR analysis for the expression of mesodermal markers (A) and hematopoietic and endothelial markers (B).
(C) RT-PCR analysis for the expression of embryonic, fetal, and adult globins in cells taken from BFU-E and CFU-E colonies obtained after differentiation of hESC
on EL08.1D2 stromal cells (similar results were obtained with UG26.1B6 and AM20.1B4 stromal cell lines). In all cases, oligonucleotides were designed with the aim
of distinguishing the human from the mouse gene, and control PCRs on murine stromal cell lines were carried out to ensure amplification of human ortholog only.
Human bone marrow (BM) and human embryo (Carnegie stage 18, Cs18) cDNA were used as positive controls. The data are presented as average ± SD, n = 3.
HBE1 denotes the 3 chain, HBZ denotes the z chain, HBA1 denotes the a chain, HBG1 denotes theg chain, HBB denotes the b chain, and HBD denotes the d chain.Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc. 91
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Hematopoietic Differentiation of hESC on Stromal CellsFigure 5. Modulation of Hematopoietic Signaling during hESC Differentiation on Stromal Cell Lines
(A) The effects of TGF-b1, TGF-b2, TGF-b3, and BMP4 on hematopoietic differentiation of hESCs cocultured with the UG26.1B6 stromal cell line measured by
changes in CD45 expression. The data are presented as average ± SD, n = 3. Significance between each sample and the control (0 ng/ml) was calculated by using
Student’s t test.
(B) The effects of TGF-b1 and TGF-b3 on hematopoietic differentiation of hESCs cocultured in the presence or absence of stromal cell lines and primary cells
derived from the AGM and FL region measured by changes in CD45 expression. The data are presented as the average of three independent experiments.92 Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc.
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TGFb3 and TGFb1 during differentiation, similar to stromal cell
lines (data not shown). Very low expression of these genes
was observed in differentiating hESC in the absence of stromal
cells (Figures 5C and 5D), suggesting that stromal cells per se
might be important for induction of endogenous TGFb1 and
TGFb3 expression during hESC differentiation. Highest TGFb1
and TGFb3 expression was observed in differentiating hESCs
that were cocultured with the AM20.1B4 cell line and primary
stromal cells obtained from the AGM/FL region, respectively
(see Figures 5C and 5D for one example on day 18 of coculture
with hESC). This correlates well with the highest expression of
murine Tgfb1 and Tgfb3 in the AM20.1B4 and AGM-derived stro-
mal cells, respectively, suggesting that feeder-produced Tgfb1
and Tgfb3 might influence the production of endogenous human
TGFb1 and TGFb3 during hESC differentiation, although this
needs to be investigated further.
Detection of hESC-Derived Hematopoietic Progenitors
in the Hematopoietic System of NOD/LtSz-Scid IL2Rgnull
Recipients
Approximately 53 105 cells derived from coculture of hESC with
the three stromal cell lines and primary stromal cells generated
from the AGM and FL region were injected intrafemorally into
NOD/LtSz-Scid IL2Rgnull recipients 24 hr after total-body irradia-
tion. As an additional control, hESC differentiated in the absence
of any stromal cells were transplanted into this murine model. Our
results show the presence of hESC-derived MSCs (Figure S3) that
might have a beneficial role on the engraftment of hESC-derived
HSCs. For this reason, we transplanted the whole cell mixture at
12 (stromal cell line cocultures) and 18 days (primary cell line co-
cultures) of differentiation shown to correspond to peak hemato-
poietic progenitor activity by coexpression of CD34 and CD31
(Figure 1D). Eight to 12 weeks after transplantation, the mice
were sacrificed, and their peripheral blood and bone marrow
from the injected and uninjected femur were analyzed by flow cy-
tometry for the presence of human CD45+ cells. Vibrant violet dye
was used to distinguish cells from debris while human peripheral
blood, mouse peripheral blood, and human peripheral blood
spiked with a small amount of mouse peripheral blood were
used as controls to set up flow cytometry gates for human and
mouse CD45+ cells, respectively (Figure 6A).
All surviving mice demonstrated human reconstitution in pe-
ripheral blood and injected and uninjected femurs (Figure 6B).
Of interest is the observation that hESC-derived cells from cocul-
ture with the AM20.1B4, UG26.1B6 primary cells from the AGM
and FL region had better survival efficiency (Figure 6B), since
more mice engrafted with these cells (6/9, 6/9, 6/6, and 7/7, re-
spectively) compared to mice injected with hESC differentiated
in the presence of EL08.1D2 cell line (only 2 out of 12 mice en-
grafted and survived). In addition, there was a higher percentage
of human CD45+ cells in the peripheral blood of mice engrafted
with hESC differentiated in the presence of AM20.1B4 when
compared to the UG26.1B6 cell line (p = 0.0129) or primary cellsfrom the AGM (p = 0.0238) or fetal liver region (p = 0.0012). The
mice engrafted with hESC differentiated in the presence of
AM20.1B4 cell line also showed a significantly higher percentage
of CD45+ cells in the left femur (p = 0.035), right femur (p = 0.051),
and peripheral blood (p = 0.0022) when compared to mice en-
grafted with hESCs differentiated in the absence of feeder cells
(Figures 6B and 6C). Significant differences in engraftment of hu-
man CD45+ cells in the right and left femurs were also observed
when mice transplanted with hESC differentiated in absence of
any feeder layers were compared to hESC cocultured with cells
derived from primary AGM and fetal liver region (p < 0.005 in all
cases), thus highlighting the role of these feeder cells in enhanc-
ing the in vivo engraftment of hESC-derived hematopoietic cells.
In all cases, there were no statistically significant differences in
engraftment efficiencies between the left and the right femur
(Figure 6B). The flow cytometry results were confirmed by PCR
of genomic DNA obtained from the femurs, spleen, and periph-
eral blood of injected mice using human chromosome 17-spe-
cific satellite sequences (Figure 6B).
Interestingly, there were no significant differences between
the mean engraftment efficiency of human CD45+ in the mice
transplanted with hESC differentiated in the presence of primary
AGM-derived cells compared to the mice transplanted with
hESC that were cocultured with UG26.1B6 or AM20.1B4 in the
right and left femur (Figures 6B and 6C). In contrast, there was
a significantly higher percentage of CD45+ cells in the left and
right femur of mice engrafted with hESCs differentiated in the
presence of fetal liver cells compared to those cocultured with
EL08.1D2 cell line (p = 0.0061). The difference between these
two experimental observations can relate to the very low engraft-
ment efficiency achieved by differentiating hESC cocultured with
EL08.1D2, which makes the difference between the primary
stromal cells and the cell line much more significant.
The human CD45+ cells from uninjected femurs and peripheral
blood were sorted using FACS Aria (BD Biosciences) and
analyzed for expression of myeloid and lymphoid markers
(Figure 6D). The coexpression of human CD13 and CD33 indi-
cated the presence of hESC-derived myeloid cells. CD2 and
CD19 are also present on these cells, suggestive of hESC-de-
rived T and B cells in the primary mouse recipients. It is known
that CD2 is expressed in up to one third of circulating monocytes
and myeloid dendritic cells in addition to being expressed in
T cells, while CD19 can also be expressed in monoblasts and
early myeloid progenitor cells; thus, single expression of these
markers, although suggestive, cannot be taken as definite proof
of lymphoid engraftment in this animal model.
Secondary transplants were carried out by taking 23 106 cells
from the bone marrow of primary recipients (engrafted with
hESC differentiated in the presence of UG26.1B6 cell line) and in-
jecting them into the femurs of secondary recipients (Figure 6E).
The flow cytometry analysis and PCR analysis confirmed the
presence of hESC-derived human cells in all surviving secondary
recipients analyzed, thereby confirming the presence of hESC-
derived HSCs in our cocultures.(C and D) Quantitative RT-PCR for the expression of murine Tgfb1 and Tgfb3 in murine stromal cells and human TGFb1 and TGFb3 during hESC differentiation in
the presence of stromal cells. The data are presented as average ± SD, n = 3. P values were calculated by using arcsine transformation. Oligonucleotides used in
the qPCR reaction were checked to ensure amplification of species-specific Tgfb1 and Tgfb3 only.Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc. 93
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Our previous work has shown that coculture of murine ESC with
intact primary AGM region resulted in a significant increase
in hematopoietic colony formation (Krassowska et al., 2006).
For the first time, we show that the coculture of hESC with pri-
mary stromal cells derived from the AGM region enhances their
hematopoietic differentiation. Of particular significance has been
the much higher efficiency of hematopoietic activity generated
after the exposure of hESC to the primary cell lines derived
from the AGM region (at least 31-fold) compared to hematopoi-
etic activity induced by previously published methods, including
the EB differentiation method, and by coculture with OP9 stromal
cells.
Various coculture methods used in this study have allowed us
to enhance the in vitro differentiation of hESC and make several
observations as outlined below. First, exposure of hESC to pri-
mary stromal cells derived from the AGM and fetal liver results
in at least 22- and 12-fold more CFCs, respectively, compared
to coculture with stromal cell lines derived from these regions.
This suggests that the coculture with the primary stromal cells
is more conducive to proliferation or induction of the type of
hematopoietic progenitor cells detectable by the in vitro CFC
assay. However, this might not necessarily be the most primitive
HSC that can be detected by in vivo assays, since this cell type is
normally quiescent under steady-state hematopoiesis. Second,
the UG26.1B6 cell line was the most efficient at enhancing
hematopoietic activity in vitro compared to the other cell lines,
AM20.1B4 and EL08.1D2. This suggests that the UG26.1B6
cell line has the capacity to maintain hematopoietic progenitors
and perhaps enhance their proliferation rather than induce he-
matopoietic differentiation per se. Third, transplantation into im-
munocompromised recipients shows that AM20.1B4 is the best
cell line for generating a significant number of circulating hESC-
derived hematopoietic progenitors compared to the UG26.2B6,
EL08.1D2, or primary stromal cells derived from the AGM and
fetal liver region, thus highlighting differences in results obtained
from in vitro and in vivo work. This could be explained by subtle
differences between stromal cell lines such as the ability to in-
duce differentiation and generate more primitive precursor cells
(perhaps applicable to the AM20.1B4 cell line) versus the ability
to induce the proliferation of existing progenitors (as in the caseof UG26.2B6 cell line and primary stromal cells). The second
influencing factor could be the difference in the progenitor cell
type(s) being detected by in vitro assays versus in vivo work.
This hypothesis is supported by our previous work in which
HPP-CFC and CFU-A assays (suggested to identify more prim-
itive progenitors than CFU-GEMM) identified AM20.1B4 as
being most efficient in inducing the differentiation of most prim-
itive hematopoietic progenitors from murine ESC (Krassowska
et al., 2006). Differentiation by coculture with the different stro-
mal cell lines might also have a significant effect on the in vivo
survival, homing, and differentiation ability of hematopoietic pro-
genitor cells. Although the primary stromal cells might generate
highly prolific hematopoietic progenitor cells, their homing to
the recipient’s bone marrow and subsequent differentiation
might not be as efficient as more primitive progenitor cells that
may be produced by AM20.1B4 cocultures.
Our functional screen for potential hematopoietic modifiers
identified a positive role for TGF-b1 and TGF-b3 in enhancing
hESC differentiation to hematopoietic lineages and implied
a negative role for BMP4, TGF-b2, and Activin A. It is well estab-
lished that BMP4 plays a critical role in the specification of hema-
topoietic cells from the mesoderm in vivo (Bhatia et al., 1999),
can modulate the proliferation and lineage potential of AGM-
derived CD34+ cells (Marshall et al., 2007), and is important
for enhanced hematopoietic differentiation of hESCs in vitro
(Wang et al., 2004; Tian et al., 2004). The role of BMP4 has
been investigated in murine ESC showing that BMP4 is required
for fate specification (posterior) within the primitive streak and in-
duction of Flk1+ mesoderm; however, it is not required for prim-
itive streak formation and specification of Flk1+ mesoderm to the
hematopoietic lineages (Nostro et al., 2008). Recent data have
suggested that only short-term BMP4 treatment is needed to ini-
tiate mesoderm induction in hESCs, and this capacity is depen-
dent on the presence of endogenous FGF and the TGF-b/Nodal/
Activin signaling pathway (Zhang et al., 2007). Longer BMP4
treatment can result in trophoblast and extraembryonic endo-
derm differentiation of hESCs. Our results corroborate published
findings and show that long treatments with BMP4 do indeed
suppress hESC differentiation via the stromal coculture method.
TGF-b1 is also known to regulate HSC proliferation and pool
size in the adult blood system (Bhatia et al., 1999), has been
shown to regulate G1/S cell-cycle progression and expressionFigure 6. Detection of hESC-Derived Cells in the Hematopoietic System of Sublethally Irradiated NOD/LtSz-Scid IL2Rgnull Recipients
(A) Flow cytometry analysis for detection of human and mouse CD45+ cells in human peripheral blood spiked with mouse peripheral blood (left panel) and the
peripheral blood of NOD/LtSz-Scid IL2Rgnull recipients that have been transplanted with hESC differentiated cells (right panel).
(B) Detection of hESC-derived cells in the left femur, right femur, peripheral blood, and/or spleen of primary mouse recipients that were injected with hESC
differentiated in the presence of UG26.1B6, AM20.1B4, and EL08.1D2 by PCR (top panel) and flow cytometry (bottom panel). Six out of nine mice showed
hESC-derived cells from coculture with AM20.1B4, and 6 out of 9 mice showed hESC-derived cells from coculture with UG26.1B6, while only 2 out of 12
mice showed hESC-derived cells from coculture with EL08.1D2. PB, peripheral blood; LF, left femur; RF, right femur; and SP, spleen. Mann-Whitney U test
was used to evaluate the differences in the engraftment efficiencies between mice engrafted with hESC differentiated in the presence of three stromal cell lines.
(C) Detection of hESC-derived cells in the left femur, right femur, and peripheral blood of primary mouse recipients that were injected with hESC differentiated in
the presence of primary stromal cells derived from the AGM and fetal liver region as well as absence of any feeder layers. PB, peripheral blood; LF, left femur; RF,
right femur; and SP, spleen. Mann-Whitney U test was used to evaluate the differences in the engraftment efficiencies between mice engrafted with hESC
differentiated in the presence or absence of various stromal cell lines.
(D) Flow cytometry analysis of peripheral blood and bone marrow from primary recipient that had received hESC cells differentiated in the presence of AM20.1B4
for presence of human-derived myeloid and lymphoid-like cells.
(E) Detection of hESC-derived cells into secondary recipients that received bone marrow transplants from primary mice injected with hESC-derived cells differ-
entiated in the presence of UG26.1B6 cell line by flow cytometry (right panel) or PCR (left panel). Ten out of twenty mice showed engraftment with hESC-derived
cells. In all cases, each individual mouse is indicated by a colored circle.Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc. 95
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HSC progenitors (Bhatia et al., 1999), and can activate Smad 5
(which is also regulated by BMP4; Ruscetti et al. [2005]). It is
known that TGF-b isoforms perform distinct functions in the
adult and throughout embryogenesis, although data elucidating
these functions are still emerging and there are few data relating
to the function of TGF-b isoforms in ESC differentiation. Studies
in murine ESC have shown that endoglin, an ancillary reporter for
the TGF-b family, is required for hemangioblast and early hema-
topoietic development (Perlingeiro, 2007) and that a close inter-
play between VEGF, TGF-b1, and Activin A signaling is required
for the generation of hematopoietic and endothelial cells from
murine ESC (Park et al., 2004). Recent data suggest that
TGF-b signaling in HSCs is modulated at multiple levels by
HOXB4, which has been shown to increase the expression levels
of several TGF-b attenuators, thus specifying the duration of the
cellular response during ESC differentiation and providing an in-
teresting mechanistic link between a hematopoietic regulator
(HOXB4) and TGF-b signaling (Schiedlmeier et al., 2007).
Our large-scale transcriptional analysis has shown that all
three stromal cell lines used in this study express TGF-b1,
TGF-b2, and TGF-b3 (Oostendorp et al., 2005b) as well as the
TGF-bR1, -R2, and -R3 receptors and TGF-b-interacting pro-
teins such as Chordin-like (Crim1). The higher expression of
human TGFb1 in the differentiating hESC cocultured with the
AM20.1B4 cell line is interesting and fits well with the highest
hematopoietic reconstitution achieved in the animal model
used in this study. Also, the highest human TGFb3was observed
in hESC cocultured with stromal cells derived from the AGM and
FL region, which correlates with the highest in vitro CFC activity
observed in this study. These observations suggest a possible
role for TGFb1 in hematopoietic progenitor engraftment and
a likely role for TGFb3 in hematopoietic progenitor proliferation.
It is known that Tgfb1 is produced by stromal cells, plays a critical
role in proliferation and differentiation of HSCs, and at low levels
is able to modulate the response of CD34+ cord blood cells to
SDF1 facilitating their SDF1-mediated retention (Basu and Brox-
meyer, 2005). Whether TGF-b1 plays a similar role in hESC differ-
entiation to hematopoietic progenitors and their subsequent
bone marrow engraftment is unknown and remains to be inves-
tigated using in vivo animal models.
The role of the AGM during hematopoietic ontogeny is tran-
sient, as HSCs formed in the AGM migrate to fetal liver, which
then provides the microenvironment for enhancing long-term re-
populating activity and engraftment to bone marrow (Takeuchi
et al., 2002). This begs the question of whether hESC-derived
hematopoietic progenitors derived after exposure to the AGM
microenvironment are capable of fulfilling the role of definitive
HSCs. To address this question, we investigated the pattern of
globin expression during hematopoietic differentiation and the
capability of the hESC-derived hematopoietic precursors to dif-
ferentiate along lymphoid and myeloid lineages. Our study con-
firmed that only embryonic and fetal globins were expressed in
the erythroid colonies, suggesting the recapitulation of early
hematopoiesis in our differentiation system. The lack of adult
globin expression in erythroid colonies could be explained with
the relatively short differentiation time used in in vitro experi-
ments (6–25 days) compared to the timing of hematopoietic de-
velopment in the developing embryo. Another factor could be the96 Cell Stem Cell 3, 85–98, July 2008 ª2008 Elsevier Inc.lack of the correct niche at the time of hematopoietic induction/
maturation, which is essential for maintaining the correct pro-
genitor type activity.
Two previous studies have indicated that hESC-derived he-
matopoietic cells are capable of long-term engraftment into
NOD/SCID recipients without genetic manipulation (Tian et al.,
2006; Wang et al., 2005). Our own studies indicated that
hESC-derived hematopoietic progenitor cells, derived by cocul-
ture with the three stromal cell lines or primary cells derived from
AGM and FL region, were capable of long-term engraftment
in NOD/LtSz-Scid IL2Rgnull recipients. Retention of true HSC
activity by hESC-derived cells was confirmed by successful
secondary engraftments into the same immunocompromised
recipients. Of interest was the observation that mice transplanted
with hESCs differentiated in the presence of AM20.1B4 stroma
showed a higher percentage of CD45+ cells in the peripheral
blood when compared to animals engrafted with hESC differen-
tiated in the presence of the UG26.1B6 stroma or AGM and FL
region-derived cells as well as EL08.1D2 stromal cell line. This
suggests that different inductive cues are provided by different
microenvironments (niches) that need to be identified before
the therapeutic potential of hESC-derived cells becomes a real-
ity. The relatively small number of studies in this particular area
makes it difficult to compare engraftment efficiencies between
different groups. Notwithstanding this, the mean engraftment ef-
ficiency obtained in our study by coculture with the best cell line,
AM20.1B4, is much higher (2.06%–16.26%) than the one previ-
ously reported by Tian et al. (2006) (0.16%–1.44%). The second
study reported by Wang et al. (2005) does not report the mean
engraftment efficiency; however, only 2 of 11 engrafted mice
showed between 1% and 10% human CD45+ incorporation,
making it unlikely that their engraftment efficiency would be
more than 1%. Taken together, these data suggest that stromal
cell lines derived from hematopoietic niches such as the AGM
region provide a suitable environment for generating engraftable
HSCs from hESCs. The lack of adult globin expression and de-
finitive proof of lymphoid engraftment from hESCs do suggest
that further work is needed to prove that hESCs exposed to
the AGM microenvironment are capable of fulfilling the role
expected for definitive HSCs.
EXPERIMENTAL PROCEDURES
hESC Lines
Three cell lines, H1, H9 (both from WiCell Inc.), and hES-NCL1 (derived in our
laboratory) were used in this work. All data presented are an average of results
obtained from the three cell lines. hESCs were grown on mitotically inactivated
mouse embryonic fibroblasts with hESC medium as described in Armstrong
et al. (2006).
Stromal Cell Culture
Stromal cell lines, AM20.1B4, UG26.1B6, and EL08.1D2 were maintained as
described (Oostendorp et al., 2002b). The stromal cells used for hESC differ-
entiation experiments were normally within passage 15–20. The ECM from
each cell line was prepared by sodium deoxycholate method (Sigma, Dorset,
UK) essentially as described by Hedman et al. (1979).
Generation of Primary Stromal Cells from the AGM and Fetal Liver
Pregnant CD1 female mice were purchased from Charles River, and embryos
were dissected from the uteri at the appropriate stage. The AGM region was
dissected from day 10.5 dpc embryos using fine Tungsten needles, while fetal
Cell Stem Cell
Hematopoietic Differentiation of hESC on Stromal Cellsliver was harvested from 12.5 dpc embryos. Both the AGM and fetal liver
regions were subjected to a brief digestion in dispase (1.2 units/ml, Sigma)
and DNase I (7 mg/ml) and then plated on gelatin coated dishes in the stromal
medium described above.
Coculture of hESCs with Stromal Cells
The stromal cells were inactivated by mitomycin C treatment (10 mg/ml; 2 hr),
then replated on gelatin-coated 6-well dishes at the density of 2 3 104 cells/
cm2. The following day, hESC colonies were placed at the top of the feeder
layers (approximate density 104 cells/cm2) and covered with differentiation
medium containing knockout DMEM, 20% FCS (Hyclone), 10 mM b-mercap-
toethanol, 1 mM L-glutamine (Invitrogen), 100 mM nonessential amino acids
(Invitrogen), and 1% penicillin-streptomycin. hESCs (passage 34–45) were
used for all experiments described in this manuscript. For the blocking exper-
iments, neutralizing antibodies or chemical inhibitors were added to the differ-
entiation media for 18 days. Control wells were incubated with differentiation
medium containing a similar amount of solvent (in the case of chemical inhib-
itors) or isotype controls (in the case of neutralizing antibodies).
For the preparation of conditioned media, the cells were mitotically inacti-
vated as described above and plated on gelatin coated dishes at a density
of 56,000 cells/cm2 in stromal medium. The next day, the medium that was in-
tended for conditioning was incubated with the mitotically inactivated stromal
cells for 24 hr. The collection was repeated three times, and the pooled condi-
tioned medium was centrifuged at 1000 rpm for 5 min to remove cellular
debris.
Hematopoietic Colony Assays
All hematopoietic progenitor assays were performed according to the manu-
facturer’s instructions (Stem Cell Technologies; Vancouver, Canada). After
12–14 days incubation at 37C/5% CO2 in humidified atmosphere, the plates
were scored for CFU-G, CFU-M, CFU-GM, CFU-E, BFU-E, and CFU-GEMM
colonies under light microscope. In each experiment, a few colonies of each
type were collected by aspiration and disrupted by pipetting several times
and washing in PBS. The cell suspension was cytospined into slides (using Cy-
tospin3, Thermo Shandon) that were subsequently fixed with methanol:ace-
tone (90:10 volume) and then stained with Wright-Giemsa solution. The rest
of the cells were stained with various antibodies for hematopoietic markers
and analyzed by flow cytometry as detailed below.
Flow Cytometry Analysis
Single-cell suspensions of hESC-derived cells were prepared by incubation in
cell disassociation buffer (Invitrogen) for 15–30 min at 37C. The hESC-derived
cells were washed in staining buffer (PBS+ 5% FCS) three times before stain-
ing with either fluorochrome-conjugated or -unconjugated antibodies: CD45
FITC or APC, CD34 APC or FITC, CD14 FITC, CD33 PerCP-Cy 5.5, CD38
FITC, CD64 PE, CD31 FITC, CD56 FITC, CD235a PE, CD41A PerCP Cy5.5,
CD105-APC (eBioscience), CD44-FITC, CD29-APC, CD71-FITC, CD54-PE,
CD73-PE, CD166-PE (all from BD Biosciences, San Jose, CA), CXCR4 FITC,
unconjugated KDR/VERGFR2, and SDF1 (all from R&D Systems) for 30 min
at room temperature. In the case of unconjugated antibodies, secondary con-
jugated anti-mouse IgG/M FITC antibodies were added for another 30 min at
room temperature. Appropriate corresponding IgG/M isotype controls were
used in all experiments. Cells were resuspended in 0.5 ml of staining buffer
and stained with propidium iodide. Live cells identified by propidium iodide
exclusion were analyzed for surface marker expression using a FACS Calibur
(BDIS) and Cell Quest software or FACS Aria (BDIS), using Cell Quest and Diva
software.
Reverse Transcription PCR and LightCycler Quantitative
RT-PCR Analysis
Total RNA was extracted from hESC and differentiating cultures at days 6, 12,
18, 21, and 25 using Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. Reverse transcription and quantitative RT-PCR analysis was car-
ried out as described in Armstrong et al. (2006). All human specific are primers
shown in Table S2. Negative control samples, which lacked RT during the
preparation of cDNA, were included to monitor genomic contamination.
PCR products were resolved on 2% agarose gels, stained with ethidium bro-
mide, and visualized in a transilluminator.Analysis of NOD/LtSz-Scid IL2Rgnull Mouse Engraftment
NOD/LtSz-Scid IL2Rgnull cells were obtained from Jackson Labs and main-
tained under sterile conditions and regulations imposed by Home Office,
UK. hESCs were plated on the stromal feeder cells as described above for
12 days. The whole-cell mixture was dispersed to single cells using accutase
(Chemicon) for 20 min, and cells were passed through a filter to avoid debris.
NOD/LtSz-Scid IL2Rgnull received total body irradiation (2Sv) from an X-ray
source. Twenty-four hours after the irradiation, 500,000 hESC-derived cells
were injected into the left femur of each mouse. Eight to twelve weeks after
transplantation, the mice were culled, and single-cell suspension from BM of
each femur, spleen, and peripheral blood were collected for analysis. To pre-
pare cells for flow cytometric analysis, red cells were lysed with 0.8% ammo-
nium chloride solution, and the remaining cells were washed in PBS containing
5% FBS. The presence of human cells in the transplanted NOD/LtSz-Scid
IL2Rgnull mice was determined by flow cytometry using PerCP-Cy 5.5 conju-
gated antibody against human CD45 and APC-conjugated antibody against
mouse CD45 (both antibodies from Becton Dickinson). In parallel, PCR analy-
ses were performed to detect human DNA in mouse bone marrow. High-mo-
lecular-weight DNA was isolated using DNA extraction kit from Promega
according to the manufacturer’s instructions. PCR for the human chromosome
17-specific a-satellite was performed using forward primer 50-ACACTCTTT
TTGCAGGATCTA-30 and backward primer 50-AGCAATGTGAAACTCTGG
GA-30 (40 cycles, 94C for 30 s, 60C for 30 s, and 72C for 15 s, followed by
a final extension of 10 min at 72C).
Statistical Analysis
A number of different statistical methods were used in this manuscript. De-
tailed description of each method is outlined in the specific figure legends.
The results were considered significant if p < 0.05.
ACCESSION NUMBERS
The microarray data from the three stromal cell lines described in this manu-
script have been deposited in the Gene Expression Omnibus under ID code
GSE11589.
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with this article online at http://www.cellstemcell.com/cgi/content/full/3/1/85/
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